Barclays Downgrades Tvardi Therapeutics to Underweight, Lowers Price Target to $3

Benzinga Newsdesk www.benzinga.com Negative 93.9%

Neg 93.9% Neu 0% Pos 0%

Barclays analyst Etzer Darout downgrades Tvardi Therapeutics (NASDAQ:TVRD) from Equal-Weight to Underweight and lowers the price target from $4 to $3.